{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T11:07:21Z","timestamp":1788001641294,"version":"build-2784847793"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2020YFA0708002"],"award-info":[{"award-number":["2020YFA0708002"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Coronavirus disease 2019 (COVID-19) causes a global pandemic and has devastating effects around the world, however, there are no specific antiviral drugs and vaccines for the constant mutation of SARS-CoV-2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Purpose<\/jats:title><jats:p>In this study, we evaluted the antiviral and anti-inflammatory activities of Liushen Capsules (LS) on different novel coronavirus in vitro, studied its therapeutic effects on novel SARS-CoV-2 infected mice and observed the LS\u2019s clinical efficacy and safety in COVID-19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The antiviral and aiti-inflammatory effects of LS on the 501Y.V2\/B.1.35 and G\/478K.V1\/ B.1.617.2 strains were determined in vitro. A hACE2 mouse model of novel SARS-CoV-2 pneumonia was established. Survival rates, histological changes, inflammatory markers, lung virus titers and the expression of the key proteins in the NF-\u03baB\/MAPK signaling pathway was detected by western blotting and immumohistochemical staining in the lungs were measured. Subsequently, the disease duration, prognosis of disease, time of negative nucleic acid and the cytokines levels in serum were used to assess the efficacy of treatment with LS in patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results showed that LS (2, 1, 0.5\u00a0\u03bcg\/mL) could significantly inhibit the replication of the two SARS-CoV-2 variants and the expression of pro-inflammatory cytokines (IL-6, IL-8, IP-10, CCL-5, MIP-1\u03b1, IL-1\u03b1) induced by the virus in vitro. As for the survival experiment in mice, the survival rate of virus group was 20%, while LS-treatment groups (40, 80, 160\u00a0mg\/kg) could increase the survival rate to 60, 100 and 100%, respectively. LS (40, 80, 160\u00a0mg\/kg) could significantly decrease the lung titers in mice and it could improve the pathological changes, inhibit the excessive inflammatory mediators (IFN-\u03b1, IFN-\u03b3, IP-10, MCP-1) and the protein expression of p-NF-\u03baB p65 in mice. Moreover, LS could significantly decrease SARS-CoV-2-induced activation of p-NF-\u03baB p65, p-I\u03baB\u03b1, and p-p38 MAPK and increase the protein expression of the I\u03baB\u03b1. In addition, the patient got complete relief of symptoms after being treated with LS for 6\u00a0days and was proven with negative PCR test after being treated for 23\u00a0days. Finally, treatment with LS could reduce the release of inflammatory cytokines (IL-6, PDGF-AA\/BB, Eotaxin, MCP-1, MIP-1\u03b1, MIP-1\u03b2, GRO, CCL-5, MCP-3, IP-10, IL-1\u03b1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LS effectively alleviated novel SARS-CoV-2 or variants induced pneumonia in vitro and in vivo, and improved the prognosis of COVID-19. In light of the efficacy and safety profiles, LS could be considered for the treatment of COVID-19 with a broad-spectrum antiviral and anti-inflammatory agent.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13020-022-00598-4","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:13:27Z","timestamp":1648808007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro"],"prefix":"10.1186","volume":"17","author":[{"given":"Qinhai","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"issue":"13","key":"598_CR1","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"ZY Wu","year":"2020","unstructured":"Wu ZY, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020;323(13):1239\u201342.","journal-title":"JAMA"},{"key":"598_CR2","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. 2021 Accessed 2021."},{"key":"598_CR3","first-page":"583","volume":"586","author":"CK Wibmer","year":"2021","unstructured":"Wibmer CK, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. BioRxiv. 2021;586:583.","journal-title":"BioRxiv"},{"issue":"18","key":"598_CR4","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMcp2009249","volume":"383","author":"RT Gandhi","year":"2020","unstructured":"Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020;383(18):1757\u201366.","journal-title":"N Engl J Med"},{"key":"598_CR5","first-page":"m3379","volume":"370","author":"B Rochwerg","year":"2020","unstructured":"Rochwerg B, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.","journal-title":"BMJ"},{"issue":"1","key":"598_CR6","first-page":"105","volume":"1","author":"Y Li","year":"2020","unstructured":"Li Y, et al. Efficacy and safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial. Med (N Y). 2020;1(1):105-113.e4.","journal-title":"Med (N Y)"},{"issue":"6","key":"598_CR7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","volume":"383","author":"DR Boulware","year":"2020","unstructured":"Boulware DR, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517\u201325.","journal-title":"N Engl J Med"},{"issue":"11","key":"598_CR8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048\u201357.","journal-title":"JAMA"},{"issue":"9","key":"598_CR9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.scib.2021.01.005","volume":"66","author":"Y Dai","year":"2021","unstructured":"Dai Y, et al. A large-scale transcriptional study reveals inhibition of COVID-19 related cytokine storm by traditional Chinese medicines. Sci Bull (Beijing). 2021;66(9):884\u20138.","journal-title":"Sci Bull (Beijing)"},{"key":"598_CR10","doi-asserted-by":"crossref","first-page":"104882","DOI":"10.1016\/j.phrs.2020.104882","volume":"157","author":"D Zhang","year":"2020","unstructured":"Zhang D, et al. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence. Pharmacol Res. 2020;157:104882.","journal-title":"Pharmacol Res"},{"key":"598_CR11","doi-asserted-by":"crossref","first-page":"153242","DOI":"10.1016\/j.phymed.2020.153242","volume":"85","author":"K Hu","year":"2021","unstructured":"Hu K, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospec. Phytomedicine. 2021;85:153242.","journal-title":"Phytomedicine"},{"key":"598_CR12","doi-asserted-by":"crossref","first-page":"105127","DOI":"10.1016\/j.phrs.2020.105127","volume":"161","author":"J Tian","year":"2020","unstructured":"Tian J, et al. Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: a cohort study. Pharmacol Res. 2020;161:105127.","journal-title":"Pharmacol Res"},{"key":"598_CR13","doi-asserted-by":"crossref","first-page":"114367","DOI":"10.1016\/j.jep.2021.114367","volume":"279","author":"Q Ma","year":"2021","unstructured":"Ma Q, et al. Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2. J Ethnopharmacol. 2021;279:114367.","journal-title":"J Ethnopharmacol"},{"key":"598_CR14","doi-asserted-by":"crossref","first-page":"105290","DOI":"10.1016\/j.phrs.2020.105290","volume":"161","author":"N Shi","year":"2020","unstructured":"Shi N, et al. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retro. Pharmacol Res. 2020;161:105290.","journal-title":"Pharmacol Res"},{"key":"598_CR15","doi-asserted-by":"crossref","first-page":"105073","DOI":"10.1016\/j.phrs.2020.105073","volume":"160","author":"Q Ma","year":"2020","unstructured":"Ma Q, et al. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2. Pharmacol Res. 2020;160:105073.","journal-title":"Pharmacol Res"},{"issue":"9","key":"598_CR16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s11655-020-3426-7","volume":"26","author":"JB Wang","year":"2020","unstructured":"Wang JB, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med. 2020;26(9):648\u201355.","journal-title":"Chin J Integr Med"},{"key":"598_CR17","doi-asserted-by":"crossref","first-page":"104850","DOI":"10.1016\/j.phrs.2020.104850","volume":"158","author":"Q Ma","year":"2020","unstructured":"Ma Q, et al. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway. Pharmacol Res. 2020;158:104850.","journal-title":"Pharmacol Res"},{"key":"598_CR18","unstructured":"Li Q., L.N., Dai JJ., Di LQ., Wang HB., Yang YQ., Li JS., Xin Y., Li XD., Qu YL., Lou JW., and P. YZ, A method for detecting the Liu Shen pill by HPLC. Chinese patent CN20191012362.8., 2019."},{"issue":"8","key":"598_CR19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727\u201333.","journal-title":"N Engl J Med"},{"key":"598_CR20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Epidemiol. 1938;27:493\u20137.","journal-title":"Am J Epidemiol"},{"key":"598_CR21","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"598_CR22","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi SA, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885\u201398.","journal-title":"N Engl J Med"},{"issue":"7871","key":"598_CR23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas D, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276\u201380.","journal-title":"Nature"},{"key":"598_CR24","unstructured":"Zhu Guoqin, X.Y., Li Songlin, Clinical study on the treatment of acute pharyngitis with Liushen Pill. China Med Pharm, 2015: p. 1864\u20131867."},{"issue":"02","key":"598_CR25","first-page":"62","volume":"14","author":"G Xianghua","year":"2019","unstructured":"Xianghua G. Clinical observation of Liushen Pill combined with antibiotics in the treatment of acute tonsillitis China. J Pharm Econ. 2019;14(02):62\u20135. (published in China)","journal-title":"J Pharm Econ"},{"issue":"04","key":"598_CR26","first-page":"175","volume":"14","author":"L Mei","year":"2019","unstructured":"Mei L. The effectiveness analysis of liushen pills and licorice oral liquid in treating acute bronchitis. Chin J Misdiagnos. 2019;14(04):175\u20137.","journal-title":"Chin J Misdiagnos"},{"issue":"06","key":"598_CR27","first-page":"1687","volume":"52","author":"Q Yong","year":"2021","unstructured":"Yong Q. Clinical observation of Liushen Pill in the treatment of influenza. Chin Trad Herbal Drugs. 2021;52(06):1687\u201391.","journal-title":"Chin Trad Herbal Drugs"},{"key":"598_CR28","unstructured":"World Health Organization. Weekly epidemiological update on COVID-19\u201424 August 2021. 2021. Accessed 2021."},{"key":"598_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab124","author":"Y Liu","year":"2021","unstructured":"Liu Y, Rocklov J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med. 2021. https:\/\/doi.org\/10.1093\/jtm\/taab124.","journal-title":"J Travel Med"},{"issue":"1","key":"598_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(00)00125-X","volume":"48","author":"RW Sidwell","year":"2000","unstructured":"Sidwell RW, Smee DF. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res. 2000;48(1):1\u201316.","journal-title":"Antiviral Res"},{"issue":"6523","key":"598_CR31","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","volume":"370","author":"YJ Hou","year":"2020","unstructured":"Hou YJ, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370(6523):1464\u20138.","journal-title":"Science"},{"key":"598_CR32","first-page":"16396","volume":"267","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over alpha variant. Microbiology. 2021;267:16396.","journal-title":"Microbiology"},{"key":"598_CR33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.coviro.2021.03.009","volume":"48","author":"CY Lee","year":"2021","unstructured":"Lee CY, Lowen AC. Animal models for SARS-CoV-2. Curr Opin Virol. 2021;48:73\u201381.","journal-title":"Curr Opin Virol"},{"issue":"3","key":"598_CR34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","volume":"182","author":"J Sun","year":"2020","unstructured":"Sun J, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell. 2020;182(3):734-743.e5.","journal-title":"Cell"},{"issue":"7818","key":"598_CR35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583(7818):830\u20133.","journal-title":"Nature"},{"issue":"11","key":"598_CR36","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler ES, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21(11):1327\u201335.","journal-title":"Nat Immunol"},{"key":"598_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142032","author":"JW Golden","year":"2020","unstructured":"Golden JW, et al. Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.142032.","journal-title":"JCI Insight"},{"issue":"10","key":"598_CR38","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1515\/BC.2008.148","volume":"389","author":"S Ludwig","year":"2008","unstructured":"Ludwig S, Planz O. Influenza viruses and the NF-kappaB signaling pathway\u2014towards a novel concept of antiviral therapy. Biol Chem. 2008;389(10):1307\u201312.","journal-title":"Biol Chem"},{"key":"598_CR39","doi-asserted-by":"crossref","unstructured":"Kircheis, R., et al., NF-kappaB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients. Front Immunol, 2020. 11: p. 598444.","DOI":"10.3389\/fimmu.2020.598444"},{"issue":"2","key":"598_CR40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cell.2008.02.043","volume":"133","author":"Y Imai","year":"2008","unstructured":"Imai Y, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235\u201349.","journal-title":"Cell"},{"issue":"1","key":"598_CR41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41392-021-00575-7","volume":"6","author":"Y Wu","year":"2021","unstructured":"Wu Y, et al. RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-kappaB hyper-activation and inflammation. Signal Transduct Target Ther. 2021;6(1):167.","journal-title":"Signal Transduct Target Ther"},{"key":"598_CR42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41232-020-00146-3","volume":"40","author":"S Hojyo","year":"2020","unstructured":"Hojyo S, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40:37.","journal-title":"Inflamm Regen"},{"issue":"1","key":"598_CR43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10787-020-00773-9","volume":"29","author":"A Hariharan","year":"2021","unstructured":"Hariharan A, et al. The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients. Inflammopharmacology. 2021;29(1):91\u2013100.","journal-title":"Inflammopharmacology"},{"issue":"7","key":"598_CR44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJMc2027040","volume":"384","author":"MC Kim","year":"2021","unstructured":"Kim MC, et al. Duration of culturable SARS-CoV-2 in hospitalized patients with Covid-19. N Engl J Med. 2021;384(7):671\u20133.","journal-title":"N Engl J Med"},{"issue":"5","key":"598_CR45","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jtho.2020.02.010","volume":"15","author":"S Tian","year":"2020","unstructured":"Tian S, et al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15(5):700\u20134.","journal-title":"J Thorac Oncol"},{"issue":"10223","key":"598_CR46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395(10223):497\u2013506.","journal-title":"Lancet"},{"key":"598_CR47","doi-asserted-by":"crossref","unstructured":"Wan, S., et al., Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). 2020.","DOI":"10.1101\/2020.02.10.20021832"},{"issue":"1","key":"598_CR48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","volume":"9","author":"H Han","year":"2020","unstructured":"Han H, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123\u201330.","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"598_CR49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s10020-020-00230-x","volume":"26","author":"Y Chen","year":"2020","unstructured":"Chen Y, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med. 2020;26(1):97.","journal-title":"Mol Med"},{"issue":"1","key":"598_CR50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","volume":"76","author":"JR Tisoncik","year":"2012","unstructured":"Tisoncik JR, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16\u201332.","journal-title":"Microbiol Mol Biol Rev"},{"key":"598_CR51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","volume":"76","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro C, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43\u20139.","journal-title":"Eur J Intern Med"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-022-00598-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-022-00598-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-022-00598-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T07:54:11Z","timestamp":1675151651000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-022-00598-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1186\/s13020-022-00598-4","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University and conducted in accordance with GCP guidelines and the Declaration of Helsinki. Written informed consent was obtained from the patients or legal representatives, and the study was registered with the requisite authority (number, 2020054; Guangzhou, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript is approved by all authors for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no conflicts of interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}